scholarly journals Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement in Patients with Continuous-Flow Left Ventricular Assist Devices (LVAD)

2013 ◽  
Vol 03 (02) ◽  
pp. 97-99
Author(s):  
Ryan Cobb ◽  
Nicholas C. Cavarocchi ◽  
Hitoshi Hirose
Keyword(s):  
Percutaneous Endoscopic Gastrostomy ◽  
Continuous Flow ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Tube Placement ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Endoscopic Gastrostomy ◽  
Left Ventricular Assist ◽  
Peg Tube

Safety of percutaneous endoscopic gastrostomy tube placement in patients with continuous-flow ventricular assist devices

2016 ◽  
Vol 64 (5) ◽  
pp. 1012-1015
Author(s):  
Hesam Keshmiri ◽  
Tariq Yousuf ◽  
Rasha Issa ◽  
Sudha Kurien ◽  
Roeglio Silva
Keyword(s):  
Percutaneous Endoscopic Gastrostomy ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Tube Placement ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Assist Devices ◽  
Endoscopic Gastrostomy ◽  
Left Ventricular Assist ◽  
Peg Tube

In this retrospective study, the safety of percutaneous endoscopic gastrostomy (PEG) tube placement was evaluated as maintaining adequate nutritional support for patients with left ventricular assist devices is crucial. Nineteen patients who underwent PEG tube placement were followed for an average of 40 days. Overall, minor complications such as infections, bleeding, and PEG tube malposition occurred in just 19% of patients while the rate of major complications such as perforation was 5%. Further randomized control trials are necessary to validate this assertion that the safety of PEG placement in patients with left ventricular assist devices is similar to that of the general population.

scholarly journals Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 861
Author(s):  
Gennaro Martucci ◽  
Federico Pappalardo ◽  
Harikesh Subramanian ◽  
Giulia Ingoglia ◽  
Elena Conoscenti ◽  
...  
Keyword(s):  
Continuous Flow ◽  
Left Ventricular ◽  
Endocrine Function ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Endocrine Dysfunction ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Assist Devices ◽  
Left Ventricular Assist

Heart failure (HF) remains a leading cause of morbidity, hospitalization, and mortality worldwide. Advancement of mechanical circulatory support technology has led to the use of continuous-flow left ventricular assist devices (LVADs), reducing hospitalizations, and improving quality of life and outcomes in advanced HF. Recent studies have highlighted how metabolic and endocrine dysfunction may be a consequence of, or associated with, HF, and may represent a novel (still neglected) therapeutic target in the treatment of HF. On the other hand, it is not clear whether LVAD support, may impact the outcome by also improving organ perfusion as well as improving the neuro-hormonal state of the patients, reducing the endocrine dysfunction. Moreover, endocrine function is likely a major determinant of human homeostasis, and is a key issue in the recovery from critical illness. Care of the endocrine function may contribute to improving cardiac contractility, immune function, as well as infection control, and rehabilitation during and after a LVAD placement. In this review, data on endocrine challenges in patients carrying an LVAD are gathered to highlight pathophysiological states relevant to this setting of patients, and to summarize the current therapeutic suggestions in the treatment of thyroid dysfunction, and vitamin D, erythropoietin and testosterone administration.

Sign in / Sign up

Export Citation Format

Share Document